Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN

The BioCentury This Week podcast covers recent developments in the biotech industry, including Arrowhead's progress towards becoming a large-cap biotech and Synnovation's $2 billion deal with Novartis. The discussion highlights Arrowhead's journey, from its nanotech origins to its current focus on RNAi therapeutics, emphasizing the potential of its first commercial launch, Redemplo, and its expansion into broader patient populations with hypertriglyceridemia. The podcast further explores the increasing integration of AI in biotech venture capital, noting its impact on decision-making and the identification of new investment opportunities. Additionally, the panel discusses the FDA's challenges, including ultra-rare disease advocates' demonstration and the search for a new CBER director, as well as updates on the Trump administration's Most Favored Nation drug pricing policy.